Immunomediated Diseases and Innovative Therapies

Overview

The Immunomediated Diseases and Innovative Therapies is a heterogeneous area composed by both translational and clinical research groups which cover fields such as immunology, respiratory and systemic diseases, pharmacology, clinical biochemistry, rheumatology, advanced therapies or transfusional medicine. Its main strength derives precisely from this heterogeneity and the complementarity of the scientific interests and expertise of the different groups, many of which are currently joining efforts and synergizing in a variety of collaborative research projects.

Publications

229

total

1430

impact factor

6.25

average impact factor

Group Leader: Francisco Rodríguez Frias

team

zoom

download

The Clinical Biochemistry group has successfully achieved several goals in the development of diagnostic biomarkers and therapeutic tools related to prostate cancer (new DNA binding motifs in PTOV1), endocrine alterations (newbiomarkers for acromegaly, thyroid autoimmune disease and bariatric surgery), metabolic diseases (lysosphingolipids as biomarkers for Parkinson disease diagnostic, urea cycle disorders biomarkers), kidney diseases (validation of ApoAIb as biomarker of relapsing idiopathic nephrotic syndrome, use of EGF in IgA nephropathy assessment). Special mention must be done to the work concerning hepatitis B, C and D virus (diagnostic strategies, quasispecies complexity, studies of the effects of new mutations of hepatitis viruses, cell culture and gene therapy models), with a great impact on the understanding of these diseases. Additionally, a challenging and innovative new investigation line has started: the analysis of big data applied to define more accurate reference ranges, in collaboration with WP den Elzen, Leiden University Medical Center, The Netherlands.

20

total

88

impact factor

4^.40

average impact factor

SELECTED ARTICLES

Karimzadeh H, Kiraithe MM, Oberhardt V, Alizei ES, Bockmann J, Zur Wiesch JS, Budeus B, Hoffmann D, Wedemeyer H, Cornberg M, Krawczyk A, Rashidi-Alavijeh J, Rodriguez-Frias F, Casillas R, Buti M, Smedile A, Alavian SM, Heinold A, Emmerich F, Panning M, Gostick E, Price DA, Timm J, Hofmann M, Raziorrouh B, Thimme R, Protzer U, Roggendorf M, Neumann-Haefelin C
Mutations in Hepatitis D Virus Allow it to Escape Detection by CD8+ T Cells and Evolve at the Population Level.
Gastroenterology. 2019 May;156(6):1820-1833.
doi: 10.1053/j.gastro.2019.02.003.
IF: 19.233
Maggio V, Canovas V, Felix AJ, Gomez V, de Torres I, Semidey ME, Morote J, Noe V, Ciudad CJ, Paciucci R
A novel DNA-binding motif in Prostate Tumor Overexpressed-1 (PTOV1) required for the expression of ALDH1A1 and CCNG2 in cancer cells.
Cancer Lett. 2019 Jun 28;452:158-167.
doi: 10.1016/j.canlet.2019.03.019.
IF: 6.508
Biagetti B, Herance JR, Ferrer R, Aulinas A, Palomino-Schatzlein , Mesa J, Castano JP, Luque RM, Simo R
Metabolic Fingerprint of Acromegaly and its Potential Usefulness in Clinical Practice.
J Clin Med. 2019 Sep 26;8(10). pii: jcm8101549.
doi: 10.3390/jcm8101549.
IF: 5.688
Rando-Segura A, Buti M, Quer J, Lopez-Martinez R, Rodriguez-Frias F
Viral load measurements in individuals with hepatitis C infection: On the EASL Recommendations on Treatment of Hepatitis C 2018.
J Clin Microbiol. 2019 Dec 23;58(1). pii: JCM.01379-19.
doi: 10.1128/JCM.01379-19
IF : 4.959
Lopez-Martinez R, Arias-Garcia A, Rodriguez-Algarra F, Castellote-Belles L, Rando-Segura A, Tarraso-Urios G, Vargas-Acarino E, Montserrat-Lloan I, Blanco-Grau A, Caballero-Garralda A, Ferrer-Costa R, Pumarola-Sunye T, Buti-Ferret M, Esteban-Mur R, Quer J, Casis-Saez E, Rodriguez-Frias F
Significant Improvement in Diagnosis of Hepatitis C Virus Infection by One Step Strategy in a Central Laboratory: An Optimal Tool for Hepatitis C Elimination?
J Clin Microbiol. 2019 Dec 23;58(1). pii: JCM.01815-19.
doi: 10.1128/JCM.01815-19
IF : 4.959

View all publications

Immunomediated Diseases and Innovative Therapies

Overview

Publications

Group Leader: Francisco Rodríguez Frias

Research Areas